<DOC>
	<DOC>NCT01309477</DOC>
	<brief_summary>It is a pilot study to explore the efficacy and safety of Tacrolimus Sustained-release Capsules (ADVAGRAF) on 6-month induction therapy of Refractory Nephrotic Syndrome (RNS).</brief_summary>
	<brief_title>The Efficacy and Tolerance of Tacrolimus Sustained-release Capsules on Refractory Nephrotic Syndrome (RNS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Subjects of either sex, 1460 years of age Diagnosis of Nephrotic syndrome with hypoalbuminemia (&lt; 3.0g/dl) and heavy proteinuria (&gt; 3.5g/24hr) and exclude secondary Nephrotic syndrome Refractory Nephrotic Syndrome 1. Steroid resistant: failure to respond (either complete or partial remission) after a course of 8 weeks of 1.0 mg/kg/d prednisone or equal dose of steroid therapy 2. Steroid dependent: recurrence of nephrotic proteinuria during tapering of prednisone at a dose &gt; 10 mg/day or within the first 2 weeks after withdrawal of prednisone 3. Frequently recurrence: initial remission with steroid induction therapy, but relapsed 2 or more in 6 months or 3 or more within 12 months 4. Failure to respond (either complete or partial remission) even after CTX, MMF or CsA therapy combined with steroid eGFR â‰¥ 60 ml/min/1.73 m2 Provision of written informed consent by subject or guardian Systemic disease eGFR &lt; 60ml/min/1.73m2 Diagnosed DM Malignant tumors (except fully cured basal cell carcinoma) Familial nephritic syndrome History of significant gastrointestinal disorders (e.g. severe chronic diarrhea or active peptic ulcer disease) within 3 month prior to enter this study Any Active systemic infection or history of serious infection within one month of entry or known infection with HIV, hepatitis B, or hepatitis C Known hypersensitivity or contraindication to tacrolimus, corticosteroids Participation in another clinic trial and/or receipt of investigational drugs within 4 weeks prior to screening Pregnancy, nursing or use of a nonreliable method of contraception Inability or unwillingness to provide written informed consent Usage of immunosuppression therapy (MMF, CTX, CysA, MTX ect) for more than 1 week within 1 month prior to first randomization or intravenous MP Pulse treatment</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Refractory Nephrotic Syndrome</keyword>
	<keyword>Tacrolimus</keyword>
</DOC>